Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Subscribe To Our Newsletter & Stay Updated
